Skip to content

HansaBioMed Life Sciences OÜ

Registry code (registrikood) 12993514Private limited company (Osaühing)VAT EE101867663Activity (EMTAK 47121): Muu spetsialiseerimata jaemüükActive

Tallinn, Harju County · Financial data: annual reports up to 2025; tax data up to 2026 Q3

Revenue (2025)
€876k
▲ 14.1% vs 2024
Profit before tax (2025)
€13k
Employees, FTE (2025)
11
State taxes paid, last 4 quarters
€183k

Revenue, profit and employees, 2019–2025

€411k2019€364k2020€496k2021€511k2022€783k2023€767k2024€876k2025
YearRevenue (müügitulu)Operating profit (ärikasum)Net profitEquity (omakapital)Employees, FTE
2019€410,901€122,269€117,615€244,6669
2020€363,801€40,733€40,745€285,41111
2021€495,968€196,209€196,227€481,63811
2022€511,483€215,063€215,066€696,70410
2023€783,425€339,338€339,357€1,036,00610
2024€767,408€112,602€112,646€1,148,65210
2025€875,668€12,580€12,635€1,161,28811

Balance sheet summary

YearCashTotal assetsCurrent liabilitiesNon-current liabilitiesEquity
2019€302,077€940,468€61,902€633,900€244,666
2020€428,909€1,399,129€315,206€798,512€285,411
2021€281,602€1,293,573€222,700€589,235€481,638
2022€279,029€1,017,915€223,714€97,497€696,704
2023€599,303€1,340,702€216,405€88,291€1,036,006
2024€645,306€1,364,038€215,386€0€1,148,652
2025€791,602€1,349,561€188,273€0€1,161,288

Calculated ratios

Net profit margin = net profit ÷ revenue. Equity ratio = equity ÷ total assets. Seedata sources & methodology for how each figure is derived.

Quarterly tax and turnover data (EMTA)

QuarterState taxes paidWage taxesTurnoverEmployees
2022 Q1€35,761€37,828€174,92212
2022 Q2€35,529€37,810€143,53211
2022 Q3€35,174€37,178€130,28511
2022 Q4€34,650€36,823€176,83610
2023 Q1€32,427€34,236€228,22210
2023 Q2€33,801€36,021€211,04110
2023 Q3€34,027€36,100€203,9919
2023 Q4€31,514€33,401€271,1469
2024 Q1€32,035€33,730€160,8529
2024 Q2€32,050€33,942€181,03810
2024 Q3€46,012€48,749€209,6999
2024 Q4€33,974€35,971€258,3769
2025 Q1€35,593€37,486€262,5819
2025 Q2€40,302€42,671€240,14611
2025 Q3€46,803€49,877€317,10710
2025 Q4€45,880€48,824€331,74610
2026 Q1€44,458€47,162€258,90411
2026 Q2€46,484€49,668€283,05911
2026 Q3€46,040€48,906€204,08511

Source: EMTA quarterly published data, as of 10 October 2026. Covers state taxes and wage taxes actually paid and turnover and employee counts as declared by the company, not the annual report figures above.

About this data

In the 2025 financial year (period 1 January 2025–31 December 2025), HansaBioMed Life Sciences OÜ reported revenue of €875,668.

The company closed the 2025 financial year with a net profit of €12,635.

Revenue increased by 14.1% from €767,408 in 2024 to €875,668 in 2025.

Revenue grew at a compound annual rate of 13.4% between 2019 and 2025.

Equity accounted for 86.0% of total assets of €1,349,561 at the end of the 2025 reporting period.

With 11 full-time-equivalent employees in 2025, revenue per employee was €79,606.

Across the 4 most recent quarters declared to EMTA, up to Q3 2026, HansaBioMed Life Sciences OÜ reported €1,077,794 in turnover.

EMTA recorded 11 employees for the quarter ending Q3 2026, compared with 11 full-time-equivalent employees in the 2025 annual report.

Browse

Source

Source: Estonian e-Business Register open data (Centre of Registers and Information Systems, RIK), licence CC BY-SA 4.0, modified; Estonian Tax and Customs Board (EMTA) quarterly data. Downloaded 2026-11-16. This is not an official register extract — see ariregister.rik.ee.

Company data on this site is available under CC BY-SA 4.0.

To request a correction or the removal of this page, use the contact form. Removal requests are handled within 30 days, no justification required.